Skip to main content
Erschienen in: Tumor Biology 2/2011

01.04.2011 | Research Article

The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells

verfasst von: Xia Zhao, Weihua Yang, Changwen Shi, Wanshan Ma, Jianing Liu, Yunshan Wang, Guosheng Jiang

Erschienen in: Tumor Biology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Recent studies have demonstrated that the histone deacetylation level was closely related to the genesis and development of tumors. Thus, activating histone acetyltransferases and/or suppressing histone deacetylases (HDACs) can become an approach for tumor chemotherapy. The histone acetylation regulation often results in the inhibition of cell proliferation, induction of cell apoptosis or differentiation, and cell cycle arrest in G1 phase. It has been demonstrated recently that the traditional anticonvulsant valproic acid was an efficient class I HDAC inhibitor (HDACI); however, its antitumor effect and mechanisms on gastric cancers so far has not been elucidated clearly. In the present study, gastric carcinoma cell lines BGC-823, HGC-27, and SGC-7901 were cultured with valproic acid (VPA) in vitro. The cell morphology was observed by invert microscope, the proliferation was detected by MTT assay, the apoptosis and cell cycle were analyzed by flow cytometry assay with Annexin V/PI and PI, the activities and protein expressions of Caspase 3, Caspase 8, Caspase 9 of BGC-823 cells were detected by spectrophotometry and indirect immunofluorescence technique, respectively. The protein expressions of Cyclin A, Cyclin D1, Cyclin E, P21Waf/cip1 of BGC-823 cells were analyzed by indirect immunofluorescence assay, and messenger ribonucleic acid (mRNA) expressions were detected by RT-PCR assay. The results showed that the proliferation of three kinds of gastric carcinoma cells could be inhibited obviously by VPA, which was related to the apoptosis induction and cell cycle arrest in G1 phase. The intrinsic pathway (cytochrome C pathway) was chiefly involved in the mechanism of apoptosis, which was indicated by activation of Caspase 9 and Caspase 3. The extrinsic pathway was partially involved, with slight activation of Caspase 8. The mechanism underlying its effect on cell cycle arrest in G1 phase induction was due to the upregulation of P21Waf/cip1, Mad1 expression and downregulation of Cyclin A, c-Myc expression.
Literatur
1.
Zurück zum Zitat Spotswood HT, Turner BM. An increasingly complex code. J Clin Invest. 2002;110:577–82.PubMed Spotswood HT, Turner BM. An increasingly complex code. J Clin Invest. 2002;110:577–82.PubMed
3.
Zurück zum Zitat Gray SG, Teh BT. Histone acetylation/deacetylation and cancer: an “open” and “shut” case? Curr Mol Med. 2001;1:401–29.CrossRefPubMed Gray SG, Teh BT. Histone acetylation/deacetylation and cancer: an “open” and “shut” case? Curr Mol Med. 2001;1:401–29.CrossRefPubMed
4.
Zurück zum Zitat Marks PA, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nature. 2001;1:194–202. Marks PA, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nature. 2001;1:194–202.
5.
Zurück zum Zitat Satoh A, Toyota M, Itoh F, et al. DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers. Br J Cancer. 2002;86:1817–23.CrossRefPubMed Satoh A, Toyota M, Itoh F, et al. DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers. Br J Cancer. 2002;86:1817–23.CrossRefPubMed
6.
Zurück zum Zitat Vigushin DM, Coombes RC. Targeted histone deacetylase inhibition for cancer therapy. Curr Cancer Drug Targets. 2004;4(2):205–18.CrossRefPubMed Vigushin DM, Coombes RC. Targeted histone deacetylase inhibition for cancer therapy. Curr Cancer Drug Targets. 2004;4(2):205–18.CrossRefPubMed
7.
Zurück zum Zitat Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs. 2002;13:1–13.CrossRefPubMed Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs. 2002;13:1–13.CrossRefPubMed
8.
Zurück zum Zitat Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem. 2005;96:293–304.CrossRefPubMed Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem. 2005;96:293–304.CrossRefPubMed
10.
Zurück zum Zitat Aherne GW, Rowlands MG, Stimson L, et al. Assays for the identification and evaluation of histone acetyltransferase inhibitors. Methods. 2002;26:245–53.CrossRef Aherne GW, Rowlands MG, Stimson L, et al. Assays for the identification and evaluation of histone acetyltransferase inhibitors. Methods. 2002;26:245–53.CrossRef
11.
Zurück zum Zitat Urnov FD, Wolffe AP. Chromatin remodeling and transcriptional activation: the cast (in order of appearance). Oncogene. 2001;20:2991–3006.CrossRefPubMed Urnov FD, Wolffe AP. Chromatin remodeling and transcriptional activation: the cast (in order of appearance). Oncogene. 2001;20:2991–3006.CrossRefPubMed
12.
Zurück zum Zitat Somech R, Izraelia S, Simon AJ. Histone deacetylase inhibitors: a new tool to treat cancer. Cancer Treat Rev. 2004;30:461–72.CrossRefPubMed Somech R, Izraelia S, Simon AJ. Histone deacetylase inhibitors: a new tool to treat cancer. Cancer Treat Rev. 2004;30:461–72.CrossRefPubMed
13.
Zurück zum Zitat Yang H, Hoshino K, Sanchez-Gonzalez B, et al. Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk Res. 2005;29:739–48.CrossRefPubMed Yang H, Hoshino K, Sanchez-Gonzalez B, et al. Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk Res. 2005;29:739–48.CrossRefPubMed
14.
Zurück zum Zitat Cinatl Jr J, Kotchetkov R, Blaheta R, et al. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE (2)-C cells by valproic acid: enhancement by combination with interferon-alpha. Int J Oncol. 2002;20:97–106.PubMed Cinatl Jr J, Kotchetkov R, Blaheta R, et al. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE (2)-C cells by valproic acid: enhancement by combination with interferon-alpha. Int J Oncol. 2002;20:97–106.PubMed
15.
Zurück zum Zitat Moldenhauer A, Frank RC, Pinilla-Ibarz J, et al. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. J Leukoc Biol. 2004;76:623–33.CrossRefPubMed Moldenhauer A, Frank RC, Pinilla-Ibarz J, et al. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. J Leukoc Biol. 2004;76:623–33.CrossRefPubMed
16.
Zurück zum Zitat Kuefer R, Hofer MD, Altug V, et al. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer. 2004;90:535–41.CrossRefPubMed Kuefer R, Hofer MD, Altug V, et al. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer. 2004;90:535–41.CrossRefPubMed
17.
Zurück zum Zitat Known SH, Ahn SH, Kim YK, et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and FAS/FAS ligand expression in human acute promielocytic leukemia cells. J Biol Chem. 2002;277:2073–80.CrossRef Known SH, Ahn SH, Kim YK, et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and FAS/FAS ligand expression in human acute promielocytic leukemia cells. J Biol Chem. 2002;277:2073–80.CrossRef
18.
Zurück zum Zitat Aron JL, Parthun MR, Marucci G, et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cell concurrent with activation of Caspase 8-mediated apoptosis and downregulation of c-FLIP protein. Blood. 2003;102:652–8.CrossRefPubMed Aron JL, Parthun MR, Marucci G, et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cell concurrent with activation of Caspase 8-mediated apoptosis and downregulation of c-FLIP protein. Blood. 2003;102:652–8.CrossRefPubMed
19.
Zurück zum Zitat Chang DW, Xing Z, Capacio VL, et al. Inter-dimer processing mechanism of procaspase-8 activation. EMBO J. 2003;22:4132–42.CrossRefPubMed Chang DW, Xing Z, Capacio VL, et al. Inter-dimer processing mechanism of procaspase-8 activation. EMBO J. 2003;22:4132–42.CrossRefPubMed
20.
Zurück zum Zitat Peart MJ, Tainton KM, Rurefli AA, et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 2003;63:4460–71.PubMed Peart MJ, Tainton KM, Rurefli AA, et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 2003;63:4460–71.PubMed
21.
Zurück zum Zitat Pei XY, Dai Y, Grant S, et al. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res. 2004;10:3839–52.CrossRefPubMed Pei XY, Dai Y, Grant S, et al. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res. 2004;10:3839–52.CrossRefPubMed
22.
Zurück zum Zitat Gao LW, Zhang J, Yang WH, Wang B, Wang JW. Glaucocalyxin A induces apoptosis in human leukemia HL-60 cells through mitochondria-mediated death pathway. Toxicol In Vitro. 2010; [Epub ahead of print] Gao LW, Zhang J, Yang WH, Wang B, Wang JW. Glaucocalyxin A induces apoptosis in human leukemia HL-60 cells through mitochondria-mediated death pathway. Toxicol In Vitro. 2010; [Epub ahead of print]
23.
Zurück zum Zitat Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related tothe yeast transc riptional regulator Rpd3p. Science. 1996;272:408–11.CrossRefPubMed Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related tothe yeast transc riptional regulator Rpd3p. Science. 1996;272:408–11.CrossRefPubMed
24.
Zurück zum Zitat Abdul M, Hoosein N. Inhibition by anticonvulsants of prostate-specific antigen and interleukin-6 secretion by human prostate cancer cells. Anticancer Res. 2001;21:2045–8.PubMed Abdul M, Hoosein N. Inhibition by anticonvulsants of prostate-specific antigen and interleukin-6 secretion by human prostate cancer cells. Anticancer Res. 2001;21:2045–8.PubMed
25.
Zurück zum Zitat Rocchi P, Tonelli R, Camerin C, et al. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol Rep. 2005;13:1139–44.PubMed Rocchi P, Tonelli R, Camerin C, et al. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol Rep. 2005;13:1139–44.PubMed
26.
Zurück zum Zitat Vento R, D’Alessandro N, Giuliano M, et al. Induction of apoptosis by arachidonic acid in human retinoblastoma Y79 cells: involvement of oxidative stress. Exp Eye Res. 2000;70:503–17.CrossRefPubMed Vento R, D’Alessandro N, Giuliano M, et al. Induction of apoptosis by arachidonic acid in human retinoblastoma Y79 cells: involvement of oxidative stress. Exp Eye Res. 2000;70:503–17.CrossRefPubMed
27.
Zurück zum Zitat Gozzini A, Rovida E, Sbarba PD, et al. Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on corebinding factor—acute myeloid leukemia blasts. Cancer Res. 2003;63:8955–61.PubMed Gozzini A, Rovida E, Sbarba PD, et al. Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on corebinding factor—acute myeloid leukemia blasts. Cancer Res. 2003;63:8955–61.PubMed
28.
Zurück zum Zitat Fortunati N, Catalano MG, Arena K, et al. Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab. 2004;82:1006–9.CrossRef Fortunati N, Catalano MG, Arena K, et al. Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab. 2004;82:1006–9.CrossRef
29.
Zurück zum Zitat Luong QT, O’Kelly J, Braunstein GD, et al. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res. 2006;12:5570–7.CrossRefPubMed Luong QT, O’Kelly J, Braunstein GD, et al. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res. 2006;12:5570–7.CrossRefPubMed
30.
Zurück zum Zitat Tsou MF, Stearns T. Mechanism limiting centrosome duplication to once per cell cycle. Nature. 2006;442:947–51.CrossRefPubMed Tsou MF, Stearns T. Mechanism limiting centrosome duplication to once per cell cycle. Nature. 2006;442:947–51.CrossRefPubMed
31.
Zurück zum Zitat Catalano MG, Fortunati N, Pugliese M, et al. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab. 2005;90:1383–9.CrossRefPubMed Catalano MG, Fortunati N, Pugliese M, et al. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab. 2005;90:1383–9.CrossRefPubMed
32.
Zurück zum Zitat Zhou Q, He Q, Liang LJ. Expression of p27, Cyclin E and Cyclin A in hepatocellular carcinoma and its clinical significance. World J Gastroenterol. 2003;9:2450–4.PubMed Zhou Q, He Q, Liang LJ. Expression of p27, Cyclin E and Cyclin A in hepatocellular carcinoma and its clinical significance. World J Gastroenterol. 2003;9:2450–4.PubMed
33.
Zurück zum Zitat Macaluso M, Montanari M, Cinti C. Modulation of cell cycle components by epigenetic and genetic events. Semin Oncol. 2005;32:452–7.CrossRefPubMed Macaluso M, Montanari M, Cinti C. Modulation of cell cycle components by epigenetic and genetic events. Semin Oncol. 2005;32:452–7.CrossRefPubMed
34.
Zurück zum Zitat Pulukuri SM, Rao JS. Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2′-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells. Int J Oncol. 2005;26:863–71.PubMed Pulukuri SM, Rao JS. Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2′-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells. Int J Oncol. 2005;26:863–71.PubMed
35.
Zurück zum Zitat Gozzini A, Santini V. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts. Ann Hematol. 2005;84:54–60.CrossRefPubMed Gozzini A, Santini V. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts. Ann Hematol. 2005;84:54–60.CrossRefPubMed
36.
Zurück zum Zitat Kobayashi H, Tan EM, Fleming SE. Acetylation of histones associated with the p21WAF1/CIP1 gene by butyrate is not sufficient for p21WAF1/CIP1 gene transcription in human colorectal adenocarcinoma cells. Int J Cancer. 2004;109:207–13.CrossRefPubMed Kobayashi H, Tan EM, Fleming SE. Acetylation of histones associated with the p21WAF1/CIP1 gene by butyrate is not sufficient for p21WAF1/CIP1 gene transcription in human colorectal adenocarcinoma cells. Int J Cancer. 2004;109:207–13.CrossRefPubMed
37.
Zurück zum Zitat Park HY, Kim MK, Moon SI, et al. Cell cycle arrest and apoptotic induction in LNCaP cells by MCS-C2, novel cyclin-dependent kinase inhibitor, through p53/p21WAF1/CIP1 pathway. Cancer Sci. 2006;97:430–6.CrossRefPubMed Park HY, Kim MK, Moon SI, et al. Cell cycle arrest and apoptotic induction in LNCaP cells by MCS-C2, novel cyclin-dependent kinase inhibitor, through p53/p21WAF1/CIP1 pathway. Cancer Sci. 2006;97:430–6.CrossRefPubMed
38.
Zurück zum Zitat Nguyen HQ, Selvakumaran M, Liebermann DA, Hoffman B. Blocking c-Myc and Max expression inhibits proliferation and induces differentiation of normal and leukemic myeloid cells. Oncogene. 1995;11:2439–44.PubMed Nguyen HQ, Selvakumaran M, Liebermann DA, Hoffman B. Blocking c-Myc and Max expression inhibits proliferation and induces differentiation of normal and leukemic myeloid cells. Oncogene. 1995;11:2439–44.PubMed
39.
Zurück zum Zitat Oster SK, Ho CS, Soucie EL, Penn LZ. The Myc oncogene: marvelously complex. Adv Cancer Res. 2002;84:81–154.CrossRefPubMed Oster SK, Ho CS, Soucie EL, Penn LZ. The Myc oncogene: marvelously complex. Adv Cancer Res. 2002;84:81–154.CrossRefPubMed
40.
Zurück zum Zitat Sommer A, Hilfenhaus S, Menkel A, et al. Cell growth inhibition by the Mad/Max complex through recruitment of histone deacetylase activity. Curr Biol. 1997;7:357–65.CrossRefPubMed Sommer A, Hilfenhaus S, Menkel A, et al. Cell growth inhibition by the Mad/Max complex through recruitment of histone deacetylase activity. Curr Biol. 1997;7:357–65.CrossRefPubMed
41.
Zurück zum Zitat Hermeking H, Rago C, Schuhmacher M, et al. Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci USA. 2000;97:2229–34.CrossRefPubMed Hermeking H, Rago C, Schuhmacher M, et al. Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci USA. 2000;97:2229–34.CrossRefPubMed
42.
Zurück zum Zitat Gustavo L, James D, Rosalie S, Laszlo J, Joseph R. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature. 1997;387:422–6.CrossRef Gustavo L, James D, Rosalie S, Laszlo J, Joseph R. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature. 1997;387:422–6.CrossRef
Metadaten
Titel
The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells
verfasst von
Xia Zhao
Weihua Yang
Changwen Shi
Wanshan Ma
Jianing Liu
Yunshan Wang
Guosheng Jiang
Publikationsdatum
01.04.2011
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2011
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-010-0126-5

Weitere Artikel der Ausgabe 2/2011

Tumor Biology 2/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.